Literature DB >> 30735901

Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.

Pankaj Kumar Singh1.   

Abstract

With each newly disclosed resistance mechanism, management of cancer with previously established targets have become a "failure" oriented approach. Molecular targets such as kinases did initially provide a ray of hope against cancer but with decades of struggle between novel therapeutic agents and more sophisticated resistance mechanisms, they seem to have saturated as anti-cancer targets. Now, with more exhaustive molecular recognition techniques and approaches, epigenetic targets have accessed the centre stage as anti-cancer targets. Accordingly, several classes of epigenetic enzymes are being studied for this role and histone methyltransferases form one such class. They include a class of epigenetic enzymes which transfer methyl group from histone proteins and maintain genetic homeostasis. In cancer, several reports have deduced upregulation of different members of this family according to the tumor environment, establishing them as one of the novel anti-cancer targets. This compilation provides an updated information on several members of histone methyltransferases family as epigenetic targets for developing novel anti-cancer agents.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer; DOT1L; EHMT2; EZH2; LSDs; SETD; SMYD

Mesh:

Substances:

Year:  2019        PMID: 30735901     DOI: 10.1016/j.ejmech.2019.01.069

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  Screening for Small-Molecule Inhibitors of Histone Methyltransferases.

Authors:  Nico Cantone; Richard T Cummings; Patrick Trojer
Journal:  Methods Mol Biol       Date:  2022

2.  SMYD2 suppresses APC2 expression to activate the Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.

Authors:  Fanchao Meng; Xin Liu; Changwei Lin; Lei Xu; Jinjin Liu; Pengbo Zhang; Xiuzhong Zhang; Jun Song; Yichao Yan; Zeqiang Ren; Yi Zhang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

3.  Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.

Authors:  Garrett S Gibbons; Amarraj Chakraborty; Sierrah M Grigsby; Afoma C Umeano; Chenzhong Liao; Omar Moukha-Chafiq; Vibha Pathak; Bini Mathew; Young-Tae Lee; Yali Dou; Stephan C Schürer; Robert C Reynolds; Timothy S Snowden; Zaneta Nikolovska-Coleska
Journal:  Eur J Med Chem       Date:  2020-01-02       Impact factor: 6.514

4.  Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.

Authors:  Tithi Roy; Samuel T Boateng; Sergette Banang-Mbeumi; Pankaj K Singh; Pratik Basnet; Roxane-Cherille N Chamcheu; Federico Ladu; Isabel Chauvin; Vladimir S Spiegelman; Ronald A Hill; Konstantin G Kousoulas; Bolni Marius Nagalo; Anthony L Walker; Jean Fotie; Siva Murru; Mario Sechi; Jean Christopher Chamcheu
Journal:  Bioorg Chem       Date:  2020-12-30       Impact factor: 5.275

5.  Ranunculus ternatus Thunb extract attenuates renal fibrosis of diabetic nephropathy via inhibiting SMYD2.

Authors:  Weiwei Xu; Rui Peng; Siyu Chen; Congcong Wu; Xiaoxiao Wang; Ting Yu; Jiuying Jian; Ni Zhang; Siyang Zuo; Min Chen; Bing Guo; Lirong Liu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

6.  Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?

Authors:  Pedro A Lazo
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

7.  SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription.

Authors:  Tian Tian; Jiwei Li; Di Shi; Yupeng Zeng; Baohua Yu; Xiaoqiu Li; Ping Wei; Xiaoyan Zhou
Journal:  Cell Death Dis       Date:  2022-09-03       Impact factor: 9.685

8.  Comprehensive analysis of histone methylation modification regulators for predicting prognosis and drug sensitivity in lung adenocarcinoma.

Authors:  Ying Ye; Li Li; Qinjin Dai; Yan Liu; Lin Shen
Journal:  Front Cell Dev Biol       Date:  2022-10-03

9.  The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.

Authors:  Machiko Kojima; Kenbun Sone; Katsutoshi Oda; Ryuji Hamamoto; Syuzo Kaneko; Shinya Oki; Asako Kukita; Akira Kawata; Harunori Honjoh; Yoshiko Kawata; Tomoko Kashiyama; Masakazu Sato; Ayumi Taguchi; Yuichiro Miyamoto; Michihiro Tanikawa; Tetsushi Tsuruga; Kazunori Nagasaka; Osamu Wada-Hiraike; Yutaka Osuga; Tomoyuki Fujii
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

Review 10.  Histone methyltransferase and drug resistance in cancers.

Authors:  Cheng Yang; Jiayu Zhang; Yukui Ma; Chunfu Wu; Wei Cui; Lihui Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-08-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.